Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pancreatic cancer blood test study pulled before it began

NCT ID NCT05188573

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if a simple blood test could spot early signs of pancreatic cancer in adults aged 50 and older who were recently diagnosed with type 2 diabetes. The plan was to enroll 10,000 participants and follow up with MRI scans for those with a positive test result. However, the study was withdrawn before any volunteers were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood test for pancreatic cancer detection
What this could lead to
If validated, this test could help catch pancreatic cancer earlier in people with new-onset diabetes, potentially improving survival odds.
What could go wrong
The study was withdrawn before any participants enrolled, so no data was collected. The test's real-world accuracy and benefit remain unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Jun 2022

An estimate. Start dates often move.

Expected to finish

May 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥50 years of age or older at the time of enrollment * Willing to provide and sign the informed consent form * Must have 2 occurrences from among the below parameters of diabetes mellitus (PDMs) in past 90 days measured in outpatient setting (not in urgent care, emergency room or while inpatient): * FBG ≥126mg/dl * HbA1c ≥ 6.5% * RBG ≥200mg/dl * 2-hour post-glucose ≥ 200mg/dl (OGTT) * Must have had glycemic parameter measured in 3-18 months prior to screening without meeting DM criteria * Must be willing to provide several tubes of blood without endangering health * No history of pancreatic cancer * No history of IPMNs, other neoplastic cysts and pancreatitis * No active cancers within the past 5 years (with the exception of non-melanoma skin cancers resolved/treated \> 1 year prior to enrollment and in situ carcinomas) Exclusion Criteria: * Prior DM diagnosis * Met criteria for DM ≥91 days prior to enrollment (patients with prior gestational diabetes that has resolved are NOT acceptable to enroll) * Carried a DM diagnosis or used anti-DM medications at a time greater than or equal to 91 days prior to enrollment * Any known pancreatic lesions * Received cancer treatment within the past 5 years (with the exception of treatment of non- melanoma skin cancer), carrying a current cancer diagnosis, and/or being investigated for suspicion of past cancer recurrence. * Current chronic or acute oral steroid use * History of intra-articular steroid injections (\<1 week) of the qualifying DM blood test (allowed exception: nasal, topical, oral budesonide) * Any surgery requiring general anesthesia within 2 months of collection * Local anesthetic (including dental novocaine) within 1 week of collection * History or presence of HIV/AIDs, Hepatitis A or E within the past five years, TB, any kind of prion disorder (e.g., CJD) * Blood transfusion within 1 month * Organ transplant recipient * Currently pregnant, or pregnancy within last 12 months * Receipt of systemic immunomodulation therapy within past 12 months * Significant medical condition that in the site investigator's opinion would compromise the subject's ability to tolerate study interventions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for New-onset type II diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bluestar Genomics, Inc.

    San Diego, California, 92121, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.